Transformation Time For Minoryx With Leriglitazone Filing
EMA Submission For Rare Brain Disease Drug
The Spanish biotech, formed in 2011, is preparing for the potential European launch of leriglitazone for X-linked adrenoleukodystrophy after the EMA accepted its file.
